直肠癌术中放疗作为即刻辅助治疗:外照射可及性受限时的回顾性分析
两组4年局部无进展生存率分别为59.4%和65.4%(p=0.70),总生存和无进展生存也无差异,总体并发症率5.4%。结论提示在外照射不可及时IORT可作为有价值的治疗选择。
要点
- 外照射可及性受限时,仅用IORT的4年局部PFS为59.4%,联合EBRT为65.4%(p=0.70)。
- 两组总生存和无进展生存均无显著差异(p=0.66和p=0.51)。
- 总体并发症率低,为5.4%,IORT可作为替代选择。
核心结论
- 在外照射放疗可及性受限的情况下,IORT是局部晚期直肠癌患者的有价值治疗选择。
研究设计与样本
- 92例(53.5%)仅接受IORT(中位剂量15 Gy,范围8.4-17 Gy),80例(46.5%)接受新辅助EBRT(中位剂量50.4 Gy,范围40-50.4 Gy)联合IORT(中位剂量15 Gy,范围15-17 Gy)。
- 中位年龄65岁(范围33-82),中位随访23个月(范围0-63个月)。
主要发现
- 4年局部无进展生存率IORT组为59.4%,IORT/EBRT组为65.4%(p=0.70)。
- 总生存(p=0.66)和无进展生存(p=0.51)两组间均无差异。
- 总体并发症率为5.4%,两组毒性发生率均低。
关键数值与推荐
- IORT中位剂量15 Gy(范围8.4-17 Gy),新辅助EBRT中位剂量50.4 Gy(范围40-50.4 Gy)。
- 4年局部PFS:IORT组59.4% vs IORT/EBRT组65.4%(p=0.70)。
- OS比较p=0.66,PFS比较p=0.51,总体并发症率5.4%。
临床怎么用
- 对于局部晚期直肠癌患者,当外照射放疗不可及时,可考虑单独使用IORT作为即刻辅助治疗。
- IORT联合或不联合EBRT的局部控制、生存和毒性均相当,但需结合患者能否旅行至放疗中心个体化决策。
局限性
- 回顾性研究设计,样本来自单中心区域肿瘤中心,随访时间中位23个月。
- IORT组患者因无法前往外照射中心而分配,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant external-beam radiotherapy (EBRT) with concomitant chemotherapy is the current standard-of-care for locally-advanced rectal cancer. Intraoperative radiotherapy (IORT) is to date only recommended for pelvic recurrences or incompletely resectable tumors. We here report on patients with stage II/III rectal cancer that were treated with IORT in a regional Russian university center due to limited access to EBRT. METHODS: We retrospectively analyzed data from patients that were diagnosed with locally-advanced rectal cancer and underwent surgery from December 2012 to October 2016 at a regional oncological center in Russia (Krasnodar). During this period, access to EBRT was limited due to a temporary lack of a sufficient number of EBRT facilities. Patients unable to travel to a distant radiotherapy site received IORT alone, those that could travel received neoadjuvant external beam (chemo-) radiotherapy. Factors of interest were tumor stage, tumor differentiation, resection status, surgery type and neoadjuvant or adjuvant chemotherapy. We assessed local progression-free survival (L-PFS), PFS and overall survival (OS). RESULTS: A total of 172 patients were included in this analysis. Of those, 92 (53.5%) were treated with IORT alone (median dose: 15 Gy [8.4-17 Gy]) and 80 (46.5%) received both neoadjuvant EBRT (median dose: 50.4 Gy [40-50.4 Gy]) and IORT (median dose: 15 Gy [15-17 Gy]). The median age was 65 years [33-82]. The median follow-up was 23 months [0-63 months]. The incidence of toxicity was low in both groups with an overall complication rate of 5.4%. Local PFS at 4 years was comparable with 59.4% in the IORT group and 65.4% in the IORT/EBRT group (p = 0.70). Similarly, there was no difference in OS or PFS (p = 0.66, p = 0.51, respectively). CONCLUSIONS: IORT is a valuable option for patients with locally-advanced rectal cancer in the absence of access to EBRT.
引用
- Potemin S, Kübler J, Uvarov I, et al. Intraoperative radiotherapy as an immediate adjuvant treatment of rectal cancer due to limited access to external-beam radiotherapy. Radiat Oncol. 2020. PMID: 31924250. doi:10.1186/s13014-020-1458-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。